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Abstract

GENETIC VARIATIONS OF CYP2B6 ENZYME AND THE RESPONSE TO
MEPERIDINE IN ORAL SEDATION
By Sally Sang Guot Hua, B.A., D.M.D.
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of
Science in Dentistry at Virginia Commonwealth University.

Virginia Commonwealth University, 2009

Major Director: Teqwyn H. Brickhouse D.D.S., Ph.D
Associate Professor, Department of Pediatric Dentistry

Purpose: The purpose of this study was to determine the relationship of CYP2B6
genotype to the clinical response to meperidine in pediatric dental patients.
Methods: Twenty-five patients, ASA I/ II, 45–92 months old, received an oral
sedative regimen containing meperidine for dental treatment. The North Carolina Behavior
Rating Scale (NCBRS) and Overall Effectiveness of Sedation Scale (OESS) were used to
assess their behavior and sedation outcome. Saliva DNA samples were genotyped by PCRRFLP.

vii

Results: We found the following genotype distributions: homozygous wild-type
1*1 (n = 8, 32%), heterozygous 1*6 (n = 13, 52%), and homozygous variant 6*6 (n = 4,
16%). The genotypes were predictive of a significant decrease in the overall effectiveness
of sedation.
Conclusion: Variation in CYP2B6 appears to be predictive of less successful
sedations; wild-type individuals experienced more successful sedations than the
homozygous variant 6*6. Future research regarding the enzyme kinetics of meperidine is
needed to determine the exact enzymatic function of CYP2B6 and its variants.

viii

INTRODUCTION
According to the American Academy of Pediatric Dentistry (AAPD) moderate
sedation (formerly known as conscious sedation or sedation/analgesia) is defined as “druginduced depression of consciousness during which patients respond purposefully to verbal
commands…either alone or accompanied by light tactile stimulation” 1. In 1996, a survey
by Wilson et al of 1758 AAPD members found that 40% of members use sedation 1 to 5
times per week and 20% use sedation more than 5 times per week.2 It is estimated that
more than 1 million children have been sedated by pediatric dentists since 1985.2
Meperidine (Demerol®) is commonly used for moderate sedation in pediatric
dentistry. Meperidine’s popularity in pediatric sedation is due to its fast on-set of
approximately 15 minutes following oral administration. Peak sedation is achieved in
approximately 2 hours and subsides over several hours. 3, 4 Meperidine is an opioid
analgesic that was originally developed as an anticholinergic drug.5, 6 It acts on the mu (µ)
receptors found in the central nervous system (CNS) and on the neural elements in the
bowel.3, 7 Its opioid analgesic properties include inducing sedation, reducing reaction to
painful stimuli and reducing motor activity.3 Meperidine’s side effects include
hypotension, histamine release, nausea and vomiting, and decreased sensitivity to CO2
leading to respiratory depression.4, 7 Meperidine is primarily metabolized in the human
liver by N-demethylation to form the active metabolite normeperidine (6-N1

desmethylmeperidine), which is a potent stimulant of the CNS with no analgesic
properties.7, 8 The accumulation of normeperidine can cause neurotoxicity and produce
symptoms such as delirium, nervousness, tremor, muscle twitches and seizures.7, 8
Adverse drug reactions (ADRs) are a problem. Annually in the United States just
over 2 million ADRs are estimated to occur, with approximately 100,000 resulting in
death.9 Meperidine may contribute to this problem is some patients. A review of pediatric
dental adverse events and their contributing factors from 1969 through March 20, 1996 by
Cote et al. found 95 reported incidents: 51 resulted in death, 9 in permanent neurologic
injury, 21 in prolonged hospital stay without injury and 14 experienced no harm.10 Twentynine of the 60 incidents resulting in death and permanent neurologic injury were related to
various specialties in dentistry. 10
In 2001, Leelataweedwud et al. examined 195 cases of conscious sedation in
pediatric dentistry with the classic triple cocktail of chloral hydrate, meperidine and
hydroxyzine.11 The study found a success rate of 72%, while 23% were unsuccessful and
5% were aborted.11 There were 3% with adverse events reported which included vomiting,
desaturation, prolonged sedation and apneic episodes.11 The incidence of meperidine
ADRs is consistent with genetic variation being a partial causative factor.
Reducing ADRs is especially important when administering drugs to children in an
outpatient setting. Outpatient procedures requiring children to receive sedation include
gastrointestinal procedures, MRI scans, dental rehabilitation, and procedures completed in
the emergency department. The most commonly used opioid analgesics for moderate
sedation and analgesia are fentanyl and meperidine.12 Common adverse effects of these
2

drugs, when used as single agents can include over-sedation, respiratory depression,
mental clouding, delirium, seizures, hypotension, flushing, sweating and pruritis. While
not lethal, these effects are common with and without significant co-morbidities.
Practitioners today are unable to predict, without error, who will and who will not have an
adverse drug reaction. Using pharmacogenomics to select medications could potentially
increase therapeutic responsiveness from the 50% it is today to almost 75%, while
dramatically reducing the number of ADRs occurring each year.13 Pharmacogenetics could
revolutionize pediatric sedation, and lead to increased patient satisfaction and safety.
The cytochrome P450 monooxygenase enzyme group is a multigene family of
hepatic enzymes that are responsible for the oxidative metabolism of most medicines.
Genetic variation in the metabolic activity of these enzymes can have a negative effect on
drug efficacy and safety. Genetic polymorphisms in these and other enzymes can be used
to guide drug treatment. Figure 1 shows the following isoenzymes which are responsible
for the in vitro metabolism of the meperidine: CYP2B6, CYP3A4, and CYP2C19, with
CYP2B6 being the major enzyme that metabolizes meperidine.14 In addition its action in
the liver, CYP2B6 has also been identified in the human brain.15, 16
The CYP2B6 gene is located on chromosome 19, between 19q12 and 19q13.2 and
is composed of 9 exons.17, 18, 19 Haplotype analysis demonstrates the presence of multiple
alleles including the most common form or wild-type CYP2B6*1, and the most common
variant, CYP2B6*6.20 The activity of CYP2B6 varies between individuals and this
variation has been shown to be genetic.14 The diagnostic variant in the haplotype
CYP2B6*6, is a single nucleotide polymorphism of G to T in exon 4 that results in a
3

substitution of Gln to His at amino acid 172 (516G>T, Gln172His). 21 This change is
associated with a significant loss of function as measured by enzymatic activity.21 This
variation is clinically relevant. For example, the CYP2B6*6 variant has been reported to
affect the pharmacokinetics of efavirenz (EFV), a first line medication for treatment of
human immunodeficiency virus (HIV) patients.20, 21 Patients who are homozygous
CYP2B6*6 experience more adverse neurological events such as fatigue and mood
disorders when they are put on long term EFV therapy compared to those who are
homozygous wild type.21
In pediatric dentistry, we often encounter children who are unable to tolerate dental
procedures comfortably despite traditional behavior management techniques and adequate
local anesthesia. These children require sedation in order to receive care.1 This group of
patients, because of their age, is considered more susceptible to the adverse effects of
sedatives and narcotics on the respiratory drive, loss of protective airway reflexes and
airway obstruction.1 Currently, oral sedative agent selection is based on the patient’s
behavior, weight, medical history, physical exam and anticipated duration of the dental
procedures. Structured sedation protocols have shown to reduce morbidities and enhanced
sedation safety for pediatric patients.1 However there remains an element of
unpredictability of response to sedation. One source of variability is thought to be genetics.
It is unknown at this time what affects the CYP2B6*6 allele may have on the
pharmokinetics of meperidine. It may be associated with either an increase or decrease in
enzymatic activity, which may have varying clinical effects such as slower drug clearance,
resulting in prolonged sedation, or at the other end of the range excitability. The specific
4

aim of this study is to determine the relationship between the CYP2B6 genotype at this one
loci and clinical response to meperidine in pediatric dental patients.

5

METHOD AND MATERIALS
Sample and data collection
Twenty-five patients previously identified as requiring oral sedation for dental
treatment were recruited to participate in our research from the VCU School of Dentistry
Pediatric Dental Clinic. Patient ages ranged from 45 to 92 months at the time of treatment.
All patients were ASA I or II. The patients received an oral sedative regimen containing
meperidine combined with one or more of the following medicines: chloral hydrate,
hydroxyzine (Vistaril®) and midazolam (Versed®).
Informed consent for dental treatment under oral sedation, physical restraint and
participation in the study were obtained from the parent/guardian. An assent form was
obtained from patients who were 7 years or older for the saliva collection for CYP2B6
genetic testing. Saliva has been shown to be a viable and noninvasive method for obtaining
DNA for genetic analysis.22
Prior to the administration of oral sedation medications baseline vital signs were
obtained. After administration of the medications by the treating dental resident, the
patients and their parents/guardian remained in the pre-op room for at least 30 minutes
before the start of the dental procedure. Once in the treatment room, a blood pressure cuff
and precordial stethoscope were applied and the patient was placed on a papoose board.
Treatment began once all of the monitoring equipment was in place and the patient was
6

comfortable. The patient’s heart rate, blood pressure, and oxyhemoglobin saturation rate
(SaO2) were recorded at five minute intervals. Respiratory status and breath sounds were
monitored throughout the procedure via the precordial stethoscope by the treating pediatric
dental resident.
The behavior of the child during the treatment was recorded using the North
Carolina Behavior Rating Scale (NCBRS) and the overall effectiveness of the sedation was
rated using the Overall Effectiveness of Sedation Scale (OESS).23, 24 Vital signs,
physiological parameters and behavior scores were charted by a monitoring provider. Once
the AAPD discharge criteria1 were met the parents/guardian were escorted into the
treatment room to meet the patient. Post-operative instructions were given in verbal and
written formats to the patients and their parents/guardian.
Adverse events were defined as follows: desaturation was when the pulse oximeter,
SaO2, reading was below 95%; apnea was when there is no breath sounds via precordial
stethoscope and no visible sign of chest rise for greater than 25 seconds; excessive sedation
was when the patient required more than 30 minutes to recover; seizure, nausea and
vomiting.
Data collection was standardized prior to the start of this research. All nine
residents and full-time faculty at the VCU Pediatric Dental Department were trained and
calibrated by assessing 10 videotaped sedations that were not part of this study. The
calibration videos were of patients of record at VCU Pediatric Dental Department who
needed sedation for dental treatment. Informed consents for videotaping, physical restraint
with a papoose board and standard treatment during oral sedation were obtained from the
7

parent/guardian. The calibration training entailed watching the videos of 10 taped sedations
and assessing each patient’s behavior based on the North Carolina Behavior Rating Scale
(NCBRS) during critical events at every 5 minute intervals (see Appendix 1). The Overall
Effectiveness of Sedation Scale (OESS) was used to rate the overall success of the oral
sedation appointment ranging from “successful to unsuccessful” depending on how the
patient’s behavior affected the treatment outcome (see Appendix 1). The calibration study
indicated significant agreement (Kappa = 0.60, p < .0001).25

Genetic analysis
For each patient, 2 ml of saliva was collected using Oragen DNA (OG-300) self
DNA collection kit before and after the treatment. The patient’s saliva was collected and
the genetic analysis of CYP2B6 was done at a later date.
The DNA was extracted manually from 2ml of un-induced saliva by using QIAamp
DNA Blood Mini Kit (Valencia, CA, USA), following the manufacturer’s instructions.
PCR amplified the exonic the *6 variable region of CYP2B6.21
The genotyping analysis was done with restriction fragment length polymorphism
(RFLP). To generate the CYP2B6 526bp product, the following primers were used:
2B6*6F 5' - GGT CTG CCC ATC TAT AAA C - 3' and 2B6*6R 5' - CTG ATT CTT CAC
ATG TCT GCG - 3'. The PCR product was digested with Fermentas BseNI restriction
endonuclease enzyme. The digestion of the CYP2B6*6 variant allele 516TT amplicons
yielded two fragments of 23 and 503 bp and that of the CYP2B6*1 wildtype allele 516GG
amplicons resulted in 3 fragments of 23, 236 and 267 bp. The digestion products were
8

separated on a 2% aragose gel using electrophoresis, and banding patterns were visualized
under UV light then photodocumented.

Statistical Analyses
To compare the observed genotype frequencies with those expected under HardyWeinberg equilibrium, a chi-square test with one degree of freedom was used. The primary
aim was to test the association between CYP2B6 genotypes (homozygous for the normal
allele = 1*1, heterozygous = 1*6, and homozygous for the variant allele = 6*6) and clinical
response (behavior and sedation effectiveness), using data from the North Carolina
Behavior Rating Scale and the Overall Effectiveness of Sedation Scale.
The groups were compared using a chi-square analysis for nominal outcomes and
analysis of variance (ANOVA) for continuous outcomes. Multivariable analyses were
accomplished using a repeated-measures mixed-model ANOVA (SAS software. JMP8.0 or
SAS9.2, Cary NC). The study was approved by the Virginia Commonwealth University
Institutional Review Board Committee on Investigations Involving Human Subjects. All
clinical data were collected in the VCU Pediatric Dental Clinic and the DNA isolation was
performed at the School of Pharmacy in the laboratory of Dr. Bukaveckas.

9

RESULTS
Preliminary analyses
The demographic characteristics of the patients (n = 25) are shown in Table 1. The
patients were primarily African Americans (n = 19), with 5 Caucasians and 1 was marked
of other race. There were 16 females and 9 males. The patient’s ages ranged from 45
months to 92 months with an average age of 63.5 months at time of treatment. The
majority of subjects (68%) were ASA I status, while the rest were ASA II. The mean time
of treatment duration was 25.1 minutes with a range of 5 minutes to 63 minutes. The
patients were categorized into three genotypes and identified as: 1*1 for homogenous wildtype allele CYP2B6 (n = 8, 32%), 6*6 for homogenous variant allele (n = 4, 16%), and 1*6
for heterozygous allele (n = 13, 52%). These proportions were not different than the
expected values (25%, 50%, 25%, chi-square = 1.32, df = 2, p > 0.5) under the HardyWeinberg equilibrium. Comparing the demographic characteristics in Table 1, there were
no significant differences between the genotypes (ps > 0.09).
The medications used in the patients are described in Table 2. The triple-cocktail
combination of meperidine, midazolam, hydroxyzine was used in 68% of the cases. The
second most common drug regimen was meperidine, midazolam, and chloral hydrate, used
in 20% of the cases. The meperidine and midazolam combination and meperidine and
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hydroxyzine combination were each used once. In one case, Propofol® was used after
converting to intravenous sedation (IVS) due to failed oral sedation.
In the study cohort (n=25), 48% received restorations (n = 12), 12% extractions (n
= 3), 28% both restorations and extractions (n = 7), and in 12% of the cases the planned
procedures were not performed and the process was aborted (n = 3). There were no
instances of apnea or nausea, one instance of vomiting, two instances of desaturation and
three instances of excess sedation meaning the patients too longer than 30 minutes post-op
for recovery.

Primary analyses
The primary goal of the study was to compare the overall effectiveness of oral
sedation between three genotype groups: CYP2B6*1*1, CYP2B6*1*6 and CYP2B6*6*6.
Table 1 shows the number of individuals in each genotype and sedation effectiveness
combination. The genotype groups showed a significant difference in the overall
effectiveness (Wilcoxon rank-sum chi-square = 10.3, df = 2, p = 0.0058). As may be seen
in the table, the CYP2B6*1*1 genotype had the most effective success scores (median
effectiveness = 2) while the homozygous variant, CYP2B6*6 genotype had the worst
(median = 4).
A stepwise regression analysis of the demographic characteristics and drug
regimens was performed to determine if the difference between genotypes could also be
explained by a confounding factor. Only Vistaril (p = 0.17) and Propofol (p = 0.17)
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emerged as potential confounders (using an alpha cut-off of 0.2). Including these in the
model did not change the conclusion that effectiveness differed by genotype.

Secondary analyses
The secondary analysis focused on outcomes that were assessed on repeated
occasions during the course of each child’s procedure. These outcomes were: NCBRS,
HR, Dia-BP, Sys-BP, and SaO2. Each of these outcomes were analyzed separately with a
repeated-measures ANOVA with the following factors in the model: Event type (Baseline,
preOp, IntraOp, and PostOp), genotype (the three values), and an event*genotype
interaction.
The NCBRS was recorded on 168 occasions (between 0 and 14 times per patient)
and had a mean = 1.95, SD = 1.10. NCBRS was not assessed during the post-operative
period. The results of the repeated-measures ANOVA indicated that NCBRS did vary
across event types (p < .0001), that the genotypes did differ (p = 0.0064) and that the event
differences did not vary with genotype (p > .5, see Table 4). The estimated mean NCBRS
for each genotype and event is also shown in Table 4 and Figure 2. At baseline, the three
genotypes are not significantly different (uncorrected p-value = 0.22) but at pre-operative
phase (PreOp) they have become different (p = 0.0410). At the intraoperative period
(IntraOp), the genotypes are different (p = 0.0007). Within the genotype 1*1, there was no
difference across the events (p = 0.14) but within the 1*6 genotype there was a significant
trend (p = 0.0020) and within the 6*6 group as well (p = 0.0035).
12

The 1*1 individuals behaved with an NCBRS of 1.14 to 1.64, meaning they were
relatively quiet and had some inconsequential movements throughout the procedures.
While at the other end, those with genotype 6*6 had an average NCBRS of 2.25 baseline
and 3.71 intraoperatively. Those who possess 1*6 genotype, their NCBRS was 1.46 at
baseline and 2.27 during intra-op, which are between the values of those that have 1*1 and
6*6 genotypes.
Another way to perform this comparison is to consider the NCBRS as an ordered
multinomial response. The number and percentage are shown in Table 5. The traces for
each patient in each genotype group are shown in Figure 2. As is seen, in the genotype 1*1
group, all but one subject are NCBRS=1 at baseline and PreOp and only a few of the
subjects increase averages between 2-3 by IntraOp. The 1*6 group have traces that also
begin in the 1-2 range and then increase to the 2-3 range, or in some cases as high as
NCBRS=3 or 4. There are only n = 4 subjects in the 6*6 genotype and many seem to begin
at higher levels and all end in averages in ranges near 3-4.
The ordered multinomial outcomes may be modeled using a cumulative logit and
the GEE method for accounting for repeated measures (SAS GENMOD procedure). As is
seen in Table 6, there remain differences between the Events (p < 0.03) but the genotype
difference is less clear (p > 0.07).
The heart rate, (HR) was recorded on 300 occasions (between 2 and 19 times per
patient) and had a mean = 99.7, SD = 20.1. The results of the repeated-measures ANOVA
indicated that HR did vary across event types (p < .0001), that the genotypes did not differ
(p > 0.5) and that the event differences did not vary with genotype (p > 0.5, see Table 3).
13

The estimated mean heart rate for each event is also shown in Table 7 and Figure 6.
Tukey’s HSD indicated that the PreOp mean was not significantly different than any of the
others and that each of the others was significantly different from one another.
The systolic blood pressure (Sys-BP) was recorded on 285 occasions (between 2
and 18 times per patient) and had a mean = 121.5, SD = 21.2. The results of the repeatedmeasures ANOVA indicated that Sys-BP did vary across event types (p = .004), that the
genotypes did not differ (p > 0.8) and that the event differences did not vary with genotype
(p > 0.7, see Table 8). The estimated mean systolic BP for each event is also shown in
Table 8 and Figure 7. Tukey’s HSD indicated that only the PreOp and IntraOp values were
significantly different from one another.
The diastolic blood pressure (Dia-BP) was recorded on 285 occasions (between 2
and 18 times per patient) and had a mean = 67.5, SD = 13.8. The results of the repeatedmeasures ANOVA indicated that Dia-BP did vary across event types (p = .002), that the
genotypes did not differ (p > 0.8) and that the event differences did not vary with genotype
(p = 0.152, see Table 5). The estimated mean dia-BP for each event is also shown in Table
9 and Figure 7. Tukey’s HSD indicated that the IntraOp and PostOp values were not
different from one another, but that they were significantly higher than PreOp. Baseline
values were not different than any other event.
The oxygen saturation, SaO2, was recorded on 296 occasions (between 2 and 19
times per patient) and had a mean = 98.6, SD = 1.4. Since SaO2 was so strongly skewed,
with 90% of the values above 98, this outcome was analyzed on the log-scale and then the
summary results back transformed to the original scale. The results of the repeated14

measures ANOVA indicated that SaO2 did not vary across event types (p > .2), that the
genotypes did not differ (p > 0.6) and that the event differences did not vary with genotype
(p > .7, see Table 10). The estimated mean SaO2 for each event is also shown in Table 10
and Figure 8. There were two cases where patients experienced desaturation (<95% SaO2).
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DISCUSSION
Genetic finding:
In vitro studies of CYP2B6 have shown that all variant alleles encode functionally
active proteins.26, 27 The mean protein expression level of those who were heterozygous,
1*6, compared to that of the wild type, 1*1, did not show a significant reduction (Lang et
al 2000). However, there was a reduction of approximately 50% in protein expression for
those who were homozygous 6*6.26 This was as expected from a clinical efavirenz (EFV)
study where they found that homozygous for the *6 variant allele had more than three-fold
higher plasma drug concentration than those who were wild types.21 In a study by
Rodriguez-Novoa et al. 40% homozygous 6*6 and 19% of hetrozygous had EFV
concentration >4µg/mL, which is the toxic level. Nearly 20% of homozygous 1*1 and 2%
of homozygous 6*6 showed subtherapeutic level of EVF of <1µg/mL.28 The clinical
relevance to their research was the individuals who carried the wild type allele had
subtherapeutic concentration of EFV and were at risk for treatment failure; in contrast,
those who were homozygous 6*6 experienced neurological adverse effects more
frequently. As expected, a reduction in enzymatic function was more likely to lead to an
accumulation of EFV plasma concentration within the toxic range.
The homozygous variant CYP2B6*6, homozygous wild-type CYP2B6*1, and
heterozygous CYP2B6 genotypes were present in 16%, 32% and 52% of our population,
respectively. There were no statistical significant differences found between the
16

demographic characteristics and the genotypes (ps > 0.09). Interestingly, our study results
showed the opposite of what was expected based on in vitro studies of CYP2B6 function.
There was a statistical significance in overall effectiveness of sedation outcome, (chisquare = 10.3, df = 2, p = 0.0058) between the genotypes and their overall sedation
success. Table 3 showed that the homozygous wild-type, 1*1, had an average of overall
effectiveness score of 2, which translated to a moderately successful sedation with
moderate amount of crying and movement. In patients who were homozygotes for 6*6,
they had a mean score of 4 which was interpreted as an unsuccessful sedation outcome,
with continuous crying and movements throughout sedation, treatment performed with
difficulty, and treatment progression was hindered.
One possible explanation to the phenotypes observed in our study was the
possibility of one amino acid substitution of Gln172His mutation caused by natural singlenucleotide polymorphism enhancing the enzymatic activity of CYP2B6*6. Ariyoshi et al
in vitro enzyme kinetic study demonstrated that wild-type CYP2B6 followed the classical
hyperbolic Michaelis-Menten kinetics while the variant allele CYP2B6*6 showed the
sigmoidal kinetics with a higher Vmax value compared to that of the wild-type enzyme.29
Sigmoidal kinetics plot indicates cooperative binding of substrate to the active site which
means that the binding of one substrate molecule affects the binding of subsequent
substrate molecules. Allosteric activation by its substrate, also called homotropic
cooperativity, is also seen in CYP3A4 mediated drugs metabolism.29 This autoactivation
phenomenon appears dependent on the substrate.29
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CYP2B6*6 catalytic activity may be enhanced with meperidine. This would
explain the phenotypes observed in our study population. The patients who were
homozygous 6*6 may have metabolized meperidine at a faster rate, leading to
accumulation of normeperidine, which is associated with symptoms of neurotoxicity and
CNS excitation. Furthermore, blood levels of normeperidine:meperidine AUC ratio is
higher when it is delivered orally compared to the parenteral route.30, 31, 32 While delirium,
tremor, muscle twitches and seizures did not occur in the study, the NCBRS for patients
with the variant allele were classified as “wild” meaning defiant with undesirable
behaviors (crying, screaming, head movement, torso movement, hand movement or foot
movement at critical events). Such phenotypes can be interpreted as symptoms of CNS
stimulation by normeperidine.
It appears that CYP2B6 and its variants activity may not be generally predictable
by genetic diagnosis and is dependent upon their substrate. Our research showed that
future investigations will be needed to exactly determine the enzyme CYP2B6*6
properties toward meperidine. Future studies involve CYP2B6 variants and meperidine
pharmacokinetics may help to explain whether there is an increase in normeperidine
concentration in plasma and in peripheral blood mononuclear cells due to enhanced
enzymatic activity caused by autoactivation.

Behavioral findings
This study design fostered a reliable behavior assessment since each rater (dental
resident/faculty) was calibrated using the NCBRS and the OESS scales. The stepwise
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analysis of the demographic characteristic and drug regimens was performed and shown
that the drug regimen (Table 2) did not change the conclusion that the overall effectiveness
differed by genotype. At baseline, the NCBRS did not differ between the three genotypes.
However, at intraoperative phase, there was a difference between 3 groups as shown in
Table 4 and Figure 9. Within the wild-type allele, there was no difference across the events
(p=0.14). However, within the 1*6 and 6*6 variant alleles, there was a significant trend
difference in the events, p = 0.0020 and p = 0.0035, respectively. The NCBRS for group
1*1 started at 1 at baseline and increased to 2-3 by intraoperative phase compared to group
1*6 and 6*6 which ended with a rating of 3-4 during intraoperative phase.
The overall effectiveness of sedation score may be high for some patients. If the
patient was extremely vocal during the intraoperative length of the treatment, the treating
dentist may have rated the sedation in a more negative manner despite the fact the child
remained still and treatment proceeded without complications.

Physiologic findings
In the study population (n=25), 12% were aborted due to the patient’s behaviors.
Adverse events were reported as followed: 3 cases of excessive sedation (>30 minutes for
recovery), 1 case of vomiting, and 2 cases of desaturation. There were no instances of
apnea or nausea. In pediatric patients, nausea does not always procede vomit, which could
occur instantaneously without warning.
In oral sedation, pediatric dental patients often cry and struggle during treatment
therefore it is not uncommon to see “false alarms” meaning oxygen desaturation associated
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with movements. These “false alarms” should not be overlooked. In oral sedation,
desaturation, when the pulse oximeter reading is <95%, could happen due to many reasons
including hypoxia, hypoventilation, excessive patient movements that cause mechanical
interference, or pressure that the operator exerts on the mandible creating a mechanical
airway obstruction. In our study, the desaturation was found in two cases which was
promptly adjusted back to normal readings of >95% SaO2 saturation after adjusting the
position of the mandible and the pulse oximeter monitor.
Vital signs (heart rate, BP, and SaO2) were not statistically significant between the
different genotypes. The tendency for heart rate to increase with different event types, such
as baseline to intraoperative phase, was seen. Such a finding can be explained as during
intraoperative phase, which was when the patient was stimulated with local anesthetic
injection, rubber dam placement and dental operative procedures, the heart rate could
increase. Of critical importance was the average heart rate, 124.2 beats/minute, through out
the sedation fell within the normal range for children age 3 – 5, which is 80-125
beats/minute. In addition, the average systolic pressure was 98.52 during intraoperative
phase, which is also within the normal limits of systolic pressure for children age 3 – 5,
which is 100 mmHg.
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CONCLUSION
Many studies have focused on parameters maximizing sedation success while
minimizing ADRs associated with oral sedation medicines. However, at this time, no
studies have looked into the genetic component to oral sedation medicine, specifically
meperidine, and the sedation outcomes. We found that after the administration of oral
sedation regimens containing meperidine, individuals who carry the homozygous allele
CYP2B6*6 had less successful sedation outcomes and less desirable behaviors compared
those who were wild-type and heterozygous, who experienced better sedation outcomes.
While meperidine, at the recommended dosage, is considered safe for oral sedation, the
usefulness of CYP2B6 genetic analysis to personalize medicine may increase patient safety
and satisfaction.
Genotyping patients for the variant allele CYP2B6*6 prior to receiving meperidine
as an oral sedative for dental treatment in young children may prove to be important for
identifying individuals with genetic predisposition for sedation failure, unnecessary
anesthesia risks, economical, physical and emotional distress for both the child and the
parent. Further research investigating CYP2B6 and its variants exact enzymatic function
with respect to meperidine will contribute to the clinical significance of this enzyme.
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Table 1: Demographic Characteristics
Characteristic
n
Race
AA
19
C
5
O
1
Ethnicity
H
2
N
23
Gender
F
16
M
9
ASA
1
17
2
8
Wt (kg)
Mean
23.0
SD
6.5
Min.
15
Max
38
Duration of tx (min)
Mean
25.1
SD
17.0
Min.
5
Max
63
Age (years)
Mean
4.8
SD
1.1
Min.
3
Max
7
Age (months)
Mean
63.5
SD
13.1
Min.
45
Max
92

%
76
20
4
8
92
64
36
68
32
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Table 2: Medications
Medications
Drug regime
Dem Vis Ver
Dem Vis CH
Dem Ver
Dem Vis
Dem Vis Ver CH Pro

n

%

17
5
1
1
1

68
20
4
4
4

Local
none
L+epi
L+epi Sept
Sept

6
11
2
6

24
44
8
24

N2O use
N2O
none

21
4

84
16

Abbreviations: Dem = Demerol, Vis = Vistaril, Ver = Versed, CH = Chloral hydrate, Pro =
Propofol, L = Lidocaine, Sept = Septocaine, N20 = Nitrous oxide.
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Table 3: Comparing Overall Effectiveness
CYP2B6
genotype
1*1
1*6
6*6

Overall Effectiveness
1
2
3
4 Median
3
3
2
2
4
4
5
3
1
3
4
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Table 4: Analysis of NCBRS
Source
Event
Genotype
Event*Genotype

df Num. df Den.
F p-value
2 141.40 12.90 <.0001
2 25.36
6.20 0.0064
4 141.40
0.77 0.5437

Event
LS Mean
Genotype 1*1
Baseline
1.14
PreOp
1.14
IntraOp
1.64
Genotype 1*6
Baseline
1.46
PreOp
1.55
IntraOp
2.27
Genotype 6*6
Baseline
2.25
PreOp
2.75
IntraOp
3.71

SE

95% CI

0.38
0.38
0.26

0.39
0.39
1.10

1.90
1.90
2.19

0.31
0.29
0.20

0.84
0.98
1.85

2.07
2.13
2.70

0.50
0.50
0.38

1.25
1.75
2.94

3.25
3.75
4.49
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Table 5: Observed Counts and Percentages for each category of NCBRS outcome.

Baseline
PreOp
IntraOp
Total

6
6
28
40

NCBRS
1
2
3
Genotype 1*1 (n = 7)
(86%) 1 (14%)
0 (0%)
(86%) 1 (14%)
0 (0%)
(61%) 10 (22%) 5 (11%)
(67%) 12 (20%)
5 (8%)

(0%)
(0%)
(7%)
(5%)

7
7
46
60

Baseline
PreOp
IntraOp
Total

6
8
25
39

Genotype 1*6 (n = 13)
(60%) 3 (30%) 1 (10%)
0 (0%)
(67%) 2 (17%)
1 (8%)
1 (8%)
(41%) 13 (21%) 16 (26%) 7 (11%)
(47%) 18 (22%) 18 (22%) 8 (10%)

10
12
61
83

Baseline
PreOp
IntraOp
Total

1
1
2
4

Genotype 6*6 (n = 4)
1 (25%) 2 (50%)
0 (0%)
0 (0%) 2 (50%) 1 (25%)
2 (12%) 2 (12%) 11 (65%)
3 (12%) 6 (24%) 12 (48%)

4
4
17
25

Event

(25%)
(25%)
(12%)
(16%)

0
0
3
3

30

4

Total

Table 6: Multinomial Analysis of NCBRS
Source
Event
Genotype
Event*Genotype

df
2
2
4

Chi-sq.
7.41
5.19
3.16

p-value
0.0246
0.0748
0.5306

Predicted Percentages for each outcome:

Event
Baseline
PreOp
IntraOp
Baseline
PreOp
IntraOp
Baseline
PreOp
IntraOp

NCBRS
1
2
3
Genotype 1*1 (n = 7)
86
8
4
86
8
4
61
20
13
Genotype 1*6 (n = 13)
64
19
12
66
18
11
40
25
23
Genotype 6*6 (n = 4)
32
24
27
18
19
32
6
9
25

31

4

Total

1
1
6

100
100
100

5
5
13

100
100
100

17
31
60

100
100
100

Table 7: Analysis of Heart Rate
Source
Event
Genotype
Event*Genotype
Event
Baseline
PreOp
IntraOp
PostOp

df Num. df Den.
3 271.40
2 25.68
6 271.10
LS Mean
88.30
95.42
104.32
98.55

SE
4.36
4.53
3.42
3.44

F p-value
8.21 <.0001
0.55 0.5863
0.88 0.5098

79.62
86.41
97.32
91.51

95% CI
96.98
104.42
111.32
105.59
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Table 8: Analysis of Systolic Blood Pressure
Source
Event
Genotype
Event*Genotype
Event
Baseline
PreOp
IntraOp
PostOp

df Num. df Den.
3 255.00
2 23.62
6 254.70
LS Mean
113.86
112.78
124.02
118.11

SE
5.31
4.89
3.96
4.00

F p-value
4.52 0.0042
0.12 0.8849
0.64 0.7007

103.29
103.01
115.90
109.91

95% CI
124.42
122.56
132.14
126.31
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Table 9: Analysis of Diastolic Blood Pressure
Source
Event
Genotype
Event*Genotype
Event
Baseline
PreOp
IntraOp
PostOp

df Num. df Den.
3 258.80
2 27.71
6 258.60
LS Mean
62.46
61.18
68.83
70.31

SE
3.35
3.01
2.15
2.18

F p-value
5.02 0.0021
0.14 0.8686
1.59 0.1515

55.85
55.22
64.46
65.88

95% CI
69.08
67.13
73.20
74.75
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Table 10: Analysis of Oxygen Saturation
Source
Event
Genotype
Event*Genotype
Event
Baseline
PreOp
IntraOp
PostOp

df Num. df Den.
3 272.50
2 31.77
6 272.70
LS Mean
98.57
98.23
98.52
98.83

F p-value
1.40 0.2421
0.38 0.6847
0.62 0.7139
95% CI
97.91 99.24
97.54 98.92
98.09 98.94
98.40 99.25
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Figure 1. CYP450 isozymes responsible for meperidine metabolism. As illustrated in the
figure, it has been demonstrated in vitro that Cytochrome P450, family 2, subfamily B,
polypeptide 6 (CYP2B6) is the enzyme primarily responsible for metabolism of
meperidine 14
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Figure 2: NCBRS
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Figure 3: Traces of NCBRS for patients with genotype 1*1
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Figure 4: Traces of NCBRS for patients with genotype 1*6
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Figure 5: Traces of NCBRS for patients with genotype 6*6
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Figure 6: Analysis of Heart Rate
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Figure 7: Systolic Blood Pressure
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Figure 8: Diastolic Blood Pressure
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APPENDIX A
Behavior rating scales
The North Carolina Behavior Rating Scale and Overall Effectiveness of Sedation
Scale were used to assess clinical response to meperidine and compare the relationship of
CYP2B6 genotype and clinical response to meperidine. This appendix serves as a
description of these scales.
North Carolina Behavior Rating Scale (behavior):
The North Carolina Behavior Rating Scale (NCBRS) allows the practitioner and
assistant to assess behavior at critical events of the procedure. Behavior ranging from quiet
and cooperative (1) to wild and defiant (4) is scored at critical events.**
1. Quiet: patient is quiet and/ or sleeping with only extraneous, inconsequential
movements
2. Annoyed: patient is cooperative for treatment, but with one or two of the undesirable
behavior*
3. Upset: patient is noticeably disturbed, with two to three undesirable behaviors* making
treatment difficult but possible
4. Wild: patient is extremely defiant with presence of all undesirable behaviors* making
treatment extremely difficult.

45

* An undesirable behavior includes crying, screaming, head movement, torso movement,
hand or foot movements at critical events**
** Critical events: local anesthetic delivery (L), rubber dam placement (R), operative phase
(O) such as bur penetrating tooth to rubber dam removal and extraction, IV conversion (C).

Overall Effectiveness of Sedation Scale.
1. Successful: Patient slept throughout procedure with only minimal crying/ movement at
critical events*
2. Moderately successful: Successful sedation with moderate amount of crying and
movement but behavior did not hinder the progress of sedation
3. Mildly successful: Treatment was accomplished as planned, but due to screaming/
combative movements throughout the sedation; the progression of portions of the
treatment were hindered
4. Unsuccessful: Continuous crying/movement throughout sedation; treatment was
performed with difficulty; the progression of all treatment was hindered
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